YOUR SOURCE OF EXTERNAL INNOVATION
LDC provides biopharmaceutical companies with access to high-quality pharmaceutical leads and therapeutic antibodies based on the most innovative findings from leading research institutions. All leads come with proof-of-concept in animal models, solid IP protection and comprehensive data packages, enabling a seamless transition into a company portfolio. Industry partners have the option to stay in contact with LDC and academic partners, consulting and collaborating with them whenever needed and appropriate.
Successful de-risking
From the initial project selection and throughout the drug discovery process, LDC applies stringent go/no-go criteria, making sure that resulting leads have an above-average prospect of success.
Portfolio information
| 125 | Projects started |
| 30 | Industry deals (option/licence/co-development/spin-outs/subsidiary companies) |
| 30 | Projects actively pursued |
| 28 | Projects stopped for scientific reasons |
| > 300 | Suggestions for new projects from our academic network |
Flexible partnership structure
Depending on your needs and strategic focus we build various forms of alliances and deals including:
- Option deals
- Co-development or collaboration agreements
- Licence agreements
- Strategic partnerships
- Incubation and financing of early project ideas at LDC
- Spin-offs
Your benefits
- Gain access to highly innovative first/best-in-class therapy approaches
- Take on viable leads with preclinical proof-of-concept
- Get involved early
- Work with a team that speaks your language and understands industry requirements
- Expand your network to include excellent scientists and their research organizations
- Filter project ideas, including validation or de-validation
